We are live on ! Find out more
ATRC icon

AtriCure

252 hedge funds and large institutions have $1.47B invested in AtriCure in 2026 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 102 increasing their positions, 61 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 22

67% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 61

13% more funds holding

Funds holding: 224252 (+28)

3.23% more ownership

Funds ownership: 100.42%103.66% (+3.2%)

1% more capital invested

Capital invested by funds: $1.46B → $1.47B (+$8.4M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

94% less call options, than puts

Call options by funds: $341K | Put options by funds: $5.92M

Holders
252
Holders Change
+28
Holders Change %
+12.5%
% of All Funds
3.03%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
53
Increased
102
Reduced
61
Closed
22
Calls
$341K
Puts
$5.92M
Net Calls
-$5.58M
Net Calls Change
-$5.71M

ATRC Hedge Fund Activity: Q2 2026 in Review

252 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q2 2026, worth a combined $1.47B — up 0.57% from $1.46B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new ATRC positions and 22 closed out — a net gain of 31 holders — while 102 added to existing stakes and 61 trimmed.

The largest buyer was Arrowstreet Capital, adding an estimated $28.7M. The largest seller was VOYA Investment Management, cutting an estimated $19.5M.

  • 252 institutional investors held AtriCure (ATRC) as of Q2 2026, up from 224 in Q1 2026.
  • Funds reported $1.47B of AtriCure stock for Q2 2026, up 0.57% quarter-over-quarter.
  • 53 funds opened new AtriCure positions in Q2 2026 and 22 closed out, a net change of +31 holders.
  • The largest AtriCure buyer in Q2 2026 was Arrowstreet Capital, an estimated $28.7M added.
  • The largest AtriCure seller in Q2 2026 was VOYA Investment Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q2 2026.